Microvast Holdings announces departure of chief financial officer
Investing.com -- Shares of BioArctic AB (STO:BIOA B) climbed 4.8% following the announcement of its partner Eisai’s robust sales figures for Leqembi, which exceeded consensus estimates. The Alzheimer’s treatment generated 13.3 billion yen in the fourth quarter of 2024, surpassing the Visible Alpha consensus of 11.7 billion yen.
The higher-than-expected Leqembi sales led to a fourth-quarter royalty of 96.7 million Swedish krona for BioArctic, which is 5% above the forecasted 92 million krona and slightly ahead of the consensus of 95 million krona. This marks a 38% increase from the third quarter and a significant jump from the same quarter in the previous year, indicating a strong upward trend in revenue.
BioArctic’s royalty revenue from Leqembi has shown impressive growth, now more than ten times the amount from the same period last year. With this current pace of quarter-on-quarter growth, the company appears to be on track to meet the 2025 royalty forecast of 760 million krona, a positive sign after several quarters of tempered expectations.
RBC analysts commented on the results, saying, "Overall, we are encouraged to see a Leqembi quarter that has come in ahead of our expectations, and we hope to see significant progress in 2025 in terms of geographic expansion and an initial approval for the sub-cutaneous formulation."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.